First human tests begin for new drug DW4421

NCT ID NCT07691242

Not yet recruiting Knowledge-focused Sponsor: Daewon Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This early-stage trial evaluates the safety of multiple doses of an investigational drug called DW4421 in healthy adults aged 19 to 50. Researchers will measure how the drug moves through the body and how it is processed. The study aims to gather essential safety and dosing information before testing in patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DW4421
What this could lead to: If safe, this could pave the way for future studies of DW4421 as a potential treatment.
What could go wrong: This is an early phase 1 trial in a small number of healthy people, so it cannot prove effectiveness and may reveal unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY ADULT VOLUNTEERS

Contacts and locations

Show contact details

Locations

Chungbuk National University Hospital

Cheongju-si, North Chungcheong, South Korea

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.